Volume 2, Issue 2 (2016)                   Pharm Biomed Res 2016, 2(2): 31-46 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Alirezapour B, Rasaee M J, Jalilian A R, Paknejad M. Preparation and preliminary studies of [64Cu]-antiMUC-1 for breast cancer targeting. Pharm Biomed Res. 2016; 2 (2) :31-46
URL: http://pbr.mazums.ac.ir/article-1-99-en.html
1- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran
2- Department of Clinical Biochemistry, School of Medical Sciences, Tarbiat Modares University (TMU), Tehran, Iran
3- Department of Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Abstract:   (4125 Views)

PR81 is a monoclonal antibody that binds with high affinity to MUC1 that over expressed on breast tumors. PR81 is considered a suitable targeting molecule that was radiolabeled using Cu-64 for positron imaging studies. The monoclonal antibody was conjugated with DOTA moiety and after purification was evaluated for radiochemical purity, immunoreactivity, cell toxicity and structure integrity as well as biodistribution study in normal rats. The radiolabeled antibody prepared with acceptable radiochemical purity (> 93.2 ± 0.6 %, ITLC; specific activity; 4.6 µCi/µg), protein structure integration, significant cytotoxicity and significant immunoreactivity retention was assessed by radioimmunoassay (RIA). Animal biodistribution of the 64Cu-DOTA-PR81 was consistent with other radiolabeled antibodies. The results showed that 64Cu-DOTA-PR81 may be considered for tumor imaging for ultimate diagnosis and follow-up of MUC1 expression in oncology.

Full-Text [PDF 751 kb]   (2015 Downloads)    
Type of Study: Original Research | Subject: Radio Chemistry

Add your comments about this article : Your username or Email:

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Pharmaceutical and Biomedical Research

Designed & Developed by : Yektaweb